| DB ID | MyCo_3209 |
| Title | Performance of Candida albicans germ tube antibodies (CAGTA) and its association with (1 → 3)-β-D-glucan (BDG) for diagnosis of invasive candidiasis (IC) |
| Year | 2018 |
| PMID | 30098849 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | glabrata |
| Organism | Candida glabrata |
| Ethical Statement | All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional re-search committee (n. 59/17) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italia |
| Cohort | Here retrospectively analyzed the presence of CAGTA on−80 °C stored serum samples, where the level of BDG had been previously assessed in a prospective study conducted in the Azienda Ospedaliero–Universitaria Policlinic of Modena. In particular, here selected 29 samples from proven IC episodes and 28 from non-IC cases. |
| Cohort No. | 57 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.9 |
| Specificity | 0.75 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA Approved-Fungitell assay, Immunofluorescence assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
